{"name":"SIGA Technologies","slug":"siga-technologies","ticker":"","exchange":"","domain":"","description":"SIGA Technologies, Inc. is an American pharmaceutical company founded in 1995, based in New York City, which develops and sells pharmaceutical solutions for the antiviral treatment of smallpox, monkeypox, cowpox, and vaccinia complications.","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":4264000,"revenueGrowth":-47.4,"grossMargin":0,"rdSpend":19956159,"netIncome":23279143,"cash":219467434,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2019"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"oncology","drugs":[{"name":"Smallpox and Mpox Vaccine","genericName":"Smallpox and Mpox Vaccine","slug":"smallpox-and-mpox-vaccine","indication":"Smallpox prevention and post-exposure prophylaxis","status":"marketed"},{"name":"sevelamer carbonate oral tablet","genericName":"sevelamer carbonate oral tablet","slug":"sevelamer-carbonate-oral-tablet","indication":"Other","status":"marketed"},{"name":"Lanthanum Carbonate Chewable Tablet","genericName":"Lanthanum Carbonate Chewable Tablet","slug":"lanthanum-carbonate-chewable-tablet","indication":"Hyperphosphatemia in patients with chronic kidney disease on dialysis","status":"marketed"}]},{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"TPOXX","genericName":"TPOXX","slug":"tpoxx","indication":"Smallpox (variola virus infection)","status":"marketed"}]}],"pipeline":[{"name":"Smallpox and Mpox Vaccine","genericName":"Smallpox and Mpox Vaccine","slug":"smallpox-and-mpox-vaccine","phase":"marketed","mechanism":"This vaccine stimulates the immune system to recognize and respond to smallpox and mpox viruses by presenting viral antigens.","indications":["Smallpox prevention and post-exposure prophylaxis","Mpox (monkeypox) prevention and post-exposure prophylaxis"],"catalyst":""},{"name":"TPOXX","genericName":"TPOXX","slug":"tpoxx","phase":"marketed","mechanism":"TPOXX inhibits orthopoxvirus protein synthesis by blocking viral RNA polymerase, preventing viral replication.","indications":["Smallpox (variola virus infection)","Monkeypox (mpox)","Vaccinia virus infection and other orthopoxvirus infections"],"catalyst":""},{"name":"sevelamer carbonate oral tablet","genericName":"sevelamer carbonate oral tablet","slug":"sevelamer-carbonate-oral-tablet","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Lanthanum Carbonate Chewable Tablet","genericName":"Lanthanum Carbonate Chewable Tablet","slug":"lanthanum-carbonate-chewable-tablet","phase":"marketed","mechanism":"Lanthanum carbonate binds to phosphate in the gastrointestinal tract, forming insoluble complexes that are eliminated in feces, thereby reducing serum phosphate levels.","indications":["Hyperphosphatemia in patients with chronic kidney disease on dialysis"],"catalyst":""}],"recentEvents":[],"realNews":[{"date":"2026-03-26","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-03-14","type":"pipeline","source":"simplywall.st","summary":"Is It Time To Reassess SIGA Technologies (SIGA) After Recent Share Price Weakness? - simplywall.st","headline":"Is It Time To Reassess SIGA Technologies (SIGA) After Recent Share Price Weakness?","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-03-13","type":"earnings","source":"simplywall.st","summary":"A Look At SIGA Technologies (SIGA) Valuation After 2025 Earnings, New TPOXX Orders And Funding - simplywall.st","headline":"A Look At SIGA Technologies (SIGA) Valuation After 2025 Earnings, New TPOXX Orders And Funding","sentiment":"neutral"},{"date":"2026-03-10","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: FORM 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2026-03-10","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirwFBVV95cUxNMnlZWUNLTWtuTDVnQTVfclVHVVpucUxUSHk4N210OE9WMFY1VFZzRWMzRmhlLXdmZGxwdlJ3eEpjOXJXcFA5Y0xUS1hwcHZaZVhfRldLLVpSZ1VPSHVJMk16WDJTak10Q2lPUjByRlc2WXBTMXh5c1Y3SEZfeWEtVVRrcS1yanl5VlE2SGY4eDhpNnVZaU1fRW1KZzgzU3UyLUZLWmlURnRMbDFnZUlz?oc=5","date":"2026-01-08","type":"deal","source":"The Acquirer's Multiple","summary":"Deep Value Biodefense Pharmaceutical Company – SIGA Technologies Inc (SIGA) - The Acquirer's Multiple","headline":"Deep Value Biodefense Pharmaceutical Company – SIGA Technologies Inc (SIGA) - The Acquirer's Multiple","sentiment":"neutral"},{"date":"2025-11-06","type":"earnings","source":"SEC EDGAR","summary":"10-Q filed with SEC: FORM 10-Q","headline":"Quarterly Report (10-Q) Filed","sentiment":"neutral"},{"date":"2025-11-06","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2025-08-05","type":"earnings","source":"SEC EDGAR","summary":"10-Q filed with SEC: FORM 10-Q","headline":"Quarterly Report (10-Q) Filed","sentiment":"neutral"},{"date":"2025-08-05","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2025-06-12","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiigFBVV95cUxNU1A2TTEyLTNvdlRoOTEyUS0wcTB5MlF4SjU0a0xqc2FvMFZ6bFlKcGR5bjh6SnpkdUI4YjV0V0d5cHFKVk40WTVraXF1eUptR0JkcHpDM0tPOGpXd1k0ek9sNVUwTW1vRmhPOXFjam1RTHV4TnNOOXUxdG4xZ0lKWTlpOFhsNVpNd0E?oc=5","date":"2025-01-03","type":"regulatory","source":"Pharmaceutical Technology","summary":"SIGA’s gains approval in Japan for orthopoxvirus treatment therapy - Pharmaceutical Technology","headline":"SIGA’s gains approval in Japan for orthopoxvirus treatment therapy","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMinwFBVV95cUxPazhsQTRKcjRROGJCYlE3TEt3VU9FNEdVOTFtUmVJZjFhRDdtYUV2dEZiME1wb0ZIV0xYOHRqVEVpQjdPdEcxOTRLSDU1cWNkNHlSa3FtLVpPQ191SXN6U3VGcllWQnRkLUd1MVpUUEhCSGEyYzVuUFN6MGlqbUVjajJoZHplUUNYaDRkUVljSzNCRWhkVzFiSWFfSUd5ZE0?oc=5","date":"2024-12-12","type":"trial","source":"Fierce Pharma","summary":"Siga's smallpox antiviral Tpoxx misses the mark in another mpox study - Fierce Pharma","headline":"Siga's smallpox antiviral Tpoxx misses the mark in another mpox study","sentiment":"negative"},{"url":"https://news.google.com/rss/articles/CBMickFVX3lxTFBrOGw4NlRHVVZoODVZNHdJQmxpeEdEYVVDLVlwTXhZaTZ1VEhpY0xkenUwSXZxR2F3dEs5aTZfbTZIQlEwLXRCVHRoemNtSXVCRnMxSDV6LWhhSFEwNzlqX09tWEQzTmZQajJ4SjRQc19KZw?oc=5","date":"2024-12-12","type":"trial","source":"pharmaphorum","summary":"NIH abandons trial of SIGA's mpox drug - pharmaphorum","headline":"NIH abandons trial of SIGA's mpox drug","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiggFBVV95cUxOWkkzaEt1cmFTeU1kYXlLMlBNVkZQU1pVZDlWdVNnTWFnaTVsa3VyX2xCcTd6MER5R1FVRVA2SzBleWZ3RWJDbThoZkJCMWpCMXFSUEY4aDhNU3lmcnBYak1UVGtMSXpuZ2I2OG4yR051STR1MmNXMlZlUVdiQk5MTkZR?oc=5","date":"2024-11-30","type":"earnings","source":"Yahoo Finance","summary":"Why SIGA Technologies (SIGA) Is One of the Most Profitable Pharmaceutical Stocks Right Now? - Yahoo Finance","headline":"Why SIGA Technologies (SIGA) Is One of the Most Profitable Pharmaceutical Stocks Right Now?","sentiment":"neutral"}],"patents":[],"drugCount":4,"phaseCounts":{"marketed":4},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":{"source":"sec_edgar","revenue":4264000,"revenuePeriod":"2019-12-31","revenueHistory":[{"value":4264000,"period":"2019-12-31"},{"value":8111000,"period":"2019-09-30"},{"value":3908000,"period":"2019-06-30"},{"value":10459000,"period":"2019-03-31"},{"value":1569000,"period":"2018-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":19956159,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":23279143,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":219467434,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"ciks":null,"lastFiledAt":null},"yahoo":null}